Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells.
Chunsong YangKrzysztof WierbiłowiczNatalia M DworakSong Yi BaeSachi B TengseNicki AbianehJustin M DrakeTarek A AbbasAakrosh RatanDavid WottonBryce M PaschalPublished in: Cancer research communications (2023)
RBN2397 is a potent and selective inhibitor of PARP7 that reduces the growth of prostate cancer cells, including a model for treatment-emergent neuroendocrine prostate cancer. RBN2397 induces PARP7 trapping on chromatin, suggesting its mechanism of action might be similar to clinically used PARP1 inhibitors.